PFS, OS, and cumulative incidence of CNS progression according to test results for occult leptomeningeal dissemination
| . | Crude . | Adjusted* . | ||
|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |
| PFS | ||||
| Test for occult leptomeningeal dissemination | ||||
| Both negative | 1 | 1 | ||
| FCM+ and CC− | 1.28 | 0.56-2.94 | 1.2 | 0.49-2.94 |
| Both positive | 3.86 | 1.77-8.45 | 3.14 | 1.32-7.46 |
| FCM test | ||||
| Negative | 1 | 1 | ||
| Positive | 2.00 | 1.11-3.6 | 1.8 | 0.93-3.5 |
| OS | ||||
| Test for occult leptomeningeal dissemination | ||||
| Both negative | 1 | 1 | ||
| FCM+ and CC− | 1.08 | 0.43-2.71 | 0.94 | 0.36-2.45 |
| Both positive | 4.49 | 2.03-9.92 | 3.51 | 1.43-8.66 |
| FCM test | ||||
| Negative | 1 | 1 | ||
| Positive | 1.95 | 1.05-3.63 | 1.59 | 0.8-3.18 |
| Cumulative incidence of CNS progression | ||||
| Test for occult leptomeningeal dissemination | ||||
| Both negative | 1 | |||
| FCM+ and CC− | 8.16 | 1.45-46 | 49.59 | 1.94-1269.48 |
| Both positive | 6.00 | 0.68-53.28 | 14.94 | 1.4-159.27 |
| FCM test | ||||
| Negative | 1 | |||
| Positive | 7.29 | 1.63-32.6 | 23.75 | 2.83-199.54 |
| . | Crude . | Adjusted* . | ||
|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |
| PFS | ||||
| Test for occult leptomeningeal dissemination | ||||
| Both negative | 1 | 1 | ||
| FCM+ and CC− | 1.28 | 0.56-2.94 | 1.2 | 0.49-2.94 |
| Both positive | 3.86 | 1.77-8.45 | 3.14 | 1.32-7.46 |
| FCM test | ||||
| Negative | 1 | 1 | ||
| Positive | 2.00 | 1.11-3.6 | 1.8 | 0.93-3.5 |
| OS | ||||
| Test for occult leptomeningeal dissemination | ||||
| Both negative | 1 | 1 | ||
| FCM+ and CC− | 1.08 | 0.43-2.71 | 0.94 | 0.36-2.45 |
| Both positive | 4.49 | 2.03-9.92 | 3.51 | 1.43-8.66 |
| FCM test | ||||
| Negative | 1 | 1 | ||
| Positive | 1.95 | 1.05-3.63 | 1.59 | 0.8-3.18 |
| Cumulative incidence of CNS progression | ||||
| Test for occult leptomeningeal dissemination | ||||
| Both negative | 1 | |||
| FCM+ and CC− | 8.16 | 1.45-46 | 49.59 | 1.94-1269.48 |
| Both positive | 6.00 | 0.68-53.28 | 14.94 | 1.4-159.27 |
| FCM test | ||||
| Negative | 1 | |||
| Positive | 7.29 | 1.63-32.6 | 23.75 | 2.83-199.54 |
Effects on PFS and OS were adjusted for IPI, B symptoms, methotrexate treatment, and cytarabine treatment; effects on cumulative incidence of CNS progression were adjusted for methotrexate treatment and cytarabine treatment.